证券日报网讯科华生物（002022）7月31日在互动平台回答投资者提问时表示，公司超高效液相色谱串 联质谱系统是开放系统，但与公司质谱试剂配套使用，可以提高检测结果的稳定性和准确性。此外，公 司以超高效液相色谱串联质谱为核心技术，构建了"前处理自动化+质谱检测系统+试剂配套"的一体化 平台，覆盖营养代谢、药物浓度监测、内分泌激素检测、生物标志物分析和临床毒理研究等五大核心领 域，可为客户提供整体解决方案，能提高检测效率及检测结果的稳定性，赋能精准医疗。 ...

科华生物（002022.SZ）7月31日在投资者互动平台表示，公司与沃特世公司（Waters）有合作，在临床 质谱领域，双方合作推出了两款产品（ACQUITY UPLC I-Class PLUS/ Xevo TQ-S cronos System和 ACQUITY UPLC I-Class PLUS / Xevo TQ-Loong System）并获得了国家医疗器械注册证。本次合作中双 方采用了"双品牌"模式，将以超高效液相色谱串联质谱为核心技术，构建"前处理自动化+质谱检测+试 剂配套"的一体化平台，覆盖营养代谢、药物浓度监测、内分泌激素检测、生物标志物分析和临床毒理 研究等五大核心领域，赋能精准医疗。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司与Waters有合作吗？是关于哪方面的？ ...

数据统计显示，中证精准医疗主题指数近一个月上涨23.28%，近三个月上涨30.38%，年至今上涨 46.38%。 据了解，中证精准医疗主题指数从从事疾病筛查与诊断、数据解读、个性化治疗与用药以及其它与精准 医疗相关的上市公司中，选取市值较大的不超过50只上市公司作为样本，以反映精准医疗主题的上市公 司的整体表现。该指数以2012年06月29日为基日，以1000.0点为基点。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将 其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 跟踪CS精准医的公募基金包括：汇添富中证精准医疗A、汇添富中证精准医疗C。 金融界7月30日消息，A股三大指数收盘涨跌不一，中证精准医疗主题指数 (CS精准医，930719)下跌 1.78%，报2959.16点，成交额425.07亿元。 来源：金融界 ...

Core Insights - The article discusses the advancements and market potential of ultrasound robots, highlighting their ability to enhance diagnostic accuracy and efficiency in medical settings [3][4][5]. Group 1: Overview of Ultrasound Robots - Ultrasound robots utilize high-precision robotic arms equipped with ultrasound probes, combined with real-time imaging navigation and AI algorithms, to automate ultrasound examinations and treatments [3]. - Key technological breakthroughs include sub-millimeter motion control precision, significantly improving biopsy accuracy and reducing misdiagnosis rates [3][4]. Group 2: Market Drivers - The shortage of qualified ultrasound physicians globally drives the demand for automated devices, with a median of only 3.2 ultrasound physicians per 100,000 people [6]. - The development of precision medical treatments, such as tumor ablation, requires high accuracy in ultrasound guidance, which traditional methods struggle to provide [7]. - Rapid declines in technology costs and supportive policies have made ultrasound robots more accessible, with prices dropping from 3 million yuan in 2018 to 1.5 million yuan in 2024 [8]. Group 3: Application Scenarios - The conventional ultrasound diagnosis sector is the most mature application area, accounting for 55% of the market share, with significant growth in cardiovascular and abdominal ultrasound applications [9]. - The fastest-growing application area is in interventional treatments and surgical navigation, projected to increase from 30% in 2024 to 40% by 2031 [10]. - Remote medical applications, while currently at 15% market share, show substantial growth potential, especially with advancements in 5G technology [11]. Group 4: Market Trends and Future Outlook - North America is the largest market for ultrasound robots, expected to hold a 40% share in 2024, while the Asia-Pacific region is anticipated to grow rapidly, potentially reaching a 38% share by 2031 [12][13]. - The competitive landscape features a mix of international giants and innovative local companies, with the top five companies holding a 65% market share [14]. - Future developments will focus on creating smarter, less invasive, and more widely available ultrasound robots, with clinical penetration rates expected to rise from 3% in 2024 to 20% by 2031 [15].

Group 1 - The core viewpoint of the article highlights that Kangsheng Global (09960) has been recognized as the "Best Strategic Investment Institution in Medical Health" by Haoyue Capital, reflecting the company's achievements in strategic investments [1] - The "Medical Health Investment Excellence List" has become an important benchmark for assessing market value and brand influence in the medical health investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - Since its listing, Kangsheng Global has focused on specialized testing services, particularly in hematology, neurology, and solid tumors, reinforcing its leading position in the industry through continuous R&D investment and market expansion [1] Group 2 - In June 2024, Kangsheng Global acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, the company acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its early screening and diagnosis product pipeline [2] - In June 2025, Kangsheng Global established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in the precision medicine sector [2] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with Kangsheng Global committed to driving innovation and the synergistic development of technology and services [3] - The company aims to actively seek potential market targets, utilizing valuation gaps to integrate complementary technology firms, thereby enhancing its risk resilience and growth potential [3] - Through mergers and acquisitions, along with its own products and services, Kangsheng Global is forming a balanced strategy to navigate challenges and continue progressing [3]

Group 1 - The core viewpoint of the articles highlights the recognition of 康圣环球 (Kangsheng Global) as the "Best Strategic Investment Institution in Healthcare" by 浩悦资本 (Haoyue Capital), reflecting the company's achievements in strategic investments [1] - The "Healthcare Investment Excellence List" by Haoyue Capital has become an important benchmark for assessing market value and brand influence in the healthcare investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - 康圣环球 has maintained a leading position in specialized testing by focusing on hematology, neurology, and solid tumors, continuously expanding its business boundaries through R&D investment and market expansion to meet growing clinical demands [1] Group 2 - In June 2024, 康圣环球 acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, 康圣环球 acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its IVD product pipeline [2] - In June 2025, 康圣环球 established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in precision medicine [2] Group 3 - The Chinese healthcare industry is experiencing a structural recovery in 2025, with 康圣环球 focusing on innovation to drive the synergy between technology and services [3] - The company aims to identify potential market targets and utilize valuation gaps to integrate complementary technology firms, enhancing its risk resilience and growth potential [3] - 康圣环球 plans to adopt a dual-track approach through mergers and its own products and services, maintaining a balanced strategy in the face of challenges [3]

Core Viewpoint - The successful hosting of the academic conference on "Comprehensive Treatment of Advanced Gastrointestinal Tumors" by Rongcheng People's Hospital is a significant step towards implementing the "Healthy China 2030" strategy and promoting high-quality development in county-level healthcare [1] Group 1: Conference Details - The conference was attended by over 60 medical personnel from various healthcare institutions in the city [1] - Vice President Li Zhizhuang emphasized the importance of standardized case discussions and multidisciplinary exchanges to enhance the comprehensive diagnosis and treatment capabilities for gastrointestinal tumors in the Weihai region [1] Group 2: Expert Contributions - Professors Zhang Biyuan from Qingdao University Affiliated Hospital and Wang Yanchun from Yantai Yuhuangding Hospital delivered insightful lectures [1] - Discussions on clinical practice challenges were led by Professor Sun Yingchao from Weihai Municipal Hospital, Professor Jiang Taotao from Weihai Central Hospital, and Attending Physician Zhang Lijing from Rongcheng People's Hospital [1] Group 3: Outcomes and Impact - The successful organization of this conference not only facilitated the clinical translation and application of new technologies and concepts but also laid a solid foundation for enhancing the region's comprehensive cancer diagnosis and treatment capabilities [1]

Core Viewpoint - The stock price of Dian Diagnostics has shown a positive trend, reflecting market optimism regarding the company's growth potential in the medical services sector, particularly in third-party medical testing and innovative healthcare solutions [1][2]. Company Summary - As of July 29, 2025, Dian Diagnostics' stock price reached 16.17 yuan, marking an increase of 0.20 yuan or 1.25% from the previous trading day. The opening price was 15.95 yuan, with a high of 16.17 yuan and a low of 15.70 yuan, resulting in a trading volume of 224,100 shares and a total transaction value of 358 million yuan [1]. - The company operates in the medical services industry, providing medical diagnostic services and developing and selling in vitro diagnostic products. It has been expanding its presence in the third-party medical testing field and exploring emerging areas such as precision medicine and artificial intelligence [1]. Industry Summary - The National Healthcare Security Administration recently held a symposium to support innovative medical devices and pharmaceuticals, leading to market expectations for further policy support for the high-quality development of the medical device industry. Analysts suggest that the medical services sector has rigid demand, and profitability is expected to improve, particularly in the area of third-party testing laboratories [1].

智通财经7月28日电，据新华社，以色列耶路撒冷希伯来大学日前发布公报说，该校研究人员开发出一 类具有"降解功能"的小分子候选药物，为侵袭性乳腺癌治疗提供全新思路。公报说，这一研究不仅是在 抑制癌细胞的信号传递，更是在瓦解其信息基础结构，是精准医疗领域的重要突破。该类分子未来不仅 可能用于乳腺癌治疗，也有望拓展至其他相关恶性肿瘤和炎症性疾病。 新型分子药物有望抑制侵袭性乳腺癌 ...

Core Viewpoint - Danaher Corporation is strategically positioning itself for growth by appointing key executives focused on financial strategy and technological innovation, particularly in artificial intelligence (AI) and life sciences [5][6]. Group 1: Executive Appointments - Matthew Gugino will succeed Matthew McGrew as Chief Financial Officer (CFO) on February 28, 2026, bringing extensive experience in investor relations, financial planning, and mergers and acquisitions [2]. - Martin Stumpe has been appointed as Chief Technology and AI Officer, effective October 1, 2025, to drive the company's digital transformation and AI initiatives [3]. Group 2: AI Integration in Life Sciences - The appointment of Martin Stumpe signifies Danaher's commitment to integrating AI into its core strategy, aiming for breakthroughs in precision medicine, drug development, and AI-driven laboratory automation [5]. - This move aligns with the global trend of merging AI with healthcare, positioning Danaher competitively against industry giants like Eli Lilly and Novartis [5]. Group 3: Financial Strategy Enhancement - Danaher is leveraging Gugino's expertise to optimize capital allocation and ensure financial synergy from new acquisitions, particularly in AI technology [6]. - The company is known for its "mergers and Danaher Business System (DBS)" model, which Gugino will need to enhance to support Stumpe's AI projects through strategic financial backing [6]. - The leadership changes reflect Danaher's transition from a diversified industrial group to a technology-driven enterprise focused on data, AI, and scientific innovation [6].